Tonix's TONMYA improves fibromyalgia symptoms and physical function in Phase 3 studies
TNXP•Tonix Pharmaceuticals presented Phase 3 findings showing TONMYA improved physical symptoms, daily functioning and pain versus placebo in adults with fibromyalgia. The company said the drug was generally well tolerated, with local oral reactions the most common treatment-emergent adverse events.
1. Phase 3 findings
Tonix Pharmaceuticals presented findings from the RELIEF and RESILIENT Phase 3 trials at the IASP World Congress on Pain in Bangkok on Oct. 27, 2026. The trials showed TONMYA improved physical symptoms, daily functioning and pain versus placebo in adults with fibromyalgia.
2. Safety and availability
TONMYA was generally well tolerated, with no new safety signals; local oral reactions were the most common treatment-emergent adverse events. Commercial sales began in November 2025 following FDA approval on Aug. 15, 2025, the first new fibromyalgia medicine in over 15 years.
